655 related articles for article (PubMed ID: 34006632)
1. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
2. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
[TBL] [Abstract][Full Text] [Related]
3. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
Bonanno L; Pavan A; Dieci MV; Di Liso E; Schiavon M; Comacchio G; Attili I; Pasello G; Calabrese F; Rea F; Favaretto A; Rugge M; Guarneri V; Fassan M; Conte PF
Eur J Cancer; 2018 Sep; 101():191-200. PubMed ID: 30077124
[TBL] [Abstract][Full Text] [Related]
4. Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.
Chen P; Zhao L; Wang H; Zhang L; Zhang W; Zhu J; Yu J; Zhao S; Li W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362829
[TBL] [Abstract][Full Text] [Related]
5. Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.
Teng F; Meng X; Wang X; Yuan J; Liu S; Mu D; Zhu H; Kong L; Yu J
Oncotarget; 2016 Sep; 7(39):64318-64329. PubMed ID: 27602763
[TBL] [Abstract][Full Text] [Related]
6. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
[TBL] [Abstract][Full Text] [Related]
7. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.
Suzuki K; Kadota K; Sima CS; Nitadori J; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
J Clin Oncol; 2013 Feb; 31(4):490-8. PubMed ID: 23269987
[TBL] [Abstract][Full Text] [Related]
9. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
10. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
Chang YL; Yang CY; Huang YL; Wu CT; Yang PC
Oncotarget; 2017 Mar; 8(11):18021-18030. PubMed ID: 28152514
[TBL] [Abstract][Full Text] [Related]
11. Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes.
Iams WT; Shiuan E; Meador CB; Roth M; Bordeaux J; Vaupel C; Boyd KL; Summitt IB; Wang LL; Schneider JT; Warner JL; Zhao Z; Lovly CM
J Thorac Oncol; 2019 Nov; 14(11):1970-1981. PubMed ID: 31201935
[TBL] [Abstract][Full Text] [Related]
12. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
13. Systemic immune index predicts tumor-infiltrating lymphocyte intensity and immunotherapy response in small cell lung cancer.
Deng C; Liao J; Fu Z; Fu F; Li D; Li Y; Wang J; Chen H; Zhang Y
Transl Lung Cancer Res; 2024 Feb; 13(2):292-306. PubMed ID: 38496688
[TBL] [Abstract][Full Text] [Related]
14. CD39: the potential target in small cell lung cancer.
Chen S; Wu S; Zhang L; Zhang W; Liu Y; Chen B; Zhao S; Li W; Sun C; Wang L; Jia K; Wang H; Chen P; Wu C; Zhu J; He Y; Zhou C
Transl Lung Cancer Res; 2020 Aug; 9(4):1483-1495. PubMed ID: 32953520
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
Kiryu S; Ito Z; Suka M; Bito T; Kan S; Uchiyama K; Saruta M; Hata T; Takano Y; Fujioka S; Misawa T; Yamauchi T; Yanagisawa H; Sato N; Ohkusa T; Sugiyama H; Koido S
BMC Cancer; 2021 Nov; 21(1):1197. PubMed ID: 34758773
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated immune factors are associated with recurrence and metastasis in non-small cell lung cancer.
Yan X; Jiao SC; Zhang GQ; Guan Y; Wang JL
Cancer Gene Ther; 2017 Feb; 24(2):57-63. PubMed ID: 28084319
[TBL] [Abstract][Full Text] [Related]
17. Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma.
Kinoshita F; Takada K; Yamada Y; Oku Y; Kosai K; Ono Y; Tanaka K; Wakasu S; Oba T; Osoegawa A; Tagawa T; Shimokawa M; Oda Y; Mori M
Ann Surg Oncol; 2020 Jun; 27(6):2102-2109. PubMed ID: 31773516
[TBL] [Abstract][Full Text] [Related]
18. Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.
Shibaki R; Fujimoto D; Nozawa T; Sano A; Kitamura Y; Fukuoka J; Sato Y; Kijima T; Matsumoto H; Yokoyama T; Miura S; Hata A; Tamiya M; Taniguchi Y; Sugisaka J; Furuya N; Tanaka H; Yamamoto N; Koh Y; Akamatsu H
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38360040
[TBL] [Abstract][Full Text] [Related]
19. Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer.
Sun C; Zhang L; Zhang W; Liu Y; Chen B; Zhao S; Li W; Wang L; Ye L; Jia K; Wang H; Wu C; He Y; Zhou C
Onco Targets Ther; 2020; 13():6475-6483. PubMed ID: 32753888
[TBL] [Abstract][Full Text] [Related]
20. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
